CAS 761423-87-4
:Ipragliflozin
Beschreibung:
Ipragliflozin L-proline was approved in Japan in January 2014
for the treatment of type 2 diabetes. The drug was discovered by
Astellas Pharma and co-developed and marketed with Kotobuki
Pharmaceutical and Merck Sharp Dohme as Suglat?. Similar to
empagliflozin (XIII), ipragliflozin L-proline is a sodium-glucose
1956 A. C. Flick et al. / Bioorg. Med. Chem. 24 (2016) 1937–1980
co-transporter-2 inhibitor which prevents glucose reabsorption by
excreting excess glucose in the urine. Ipragliflozin exhibits
remarkable selectivity over SLGT-1 (>250x).
Formel:C21H21FO5S
InChl:InChI=1S/C21H21FO5S/c22-15-6-5-12(21-20(26)19(25)18(24)16(10-23)27-21)7-13(15)9-14-8-11-3-1-2-4-17(11)28-14/h1-8,16,18-21,23-26H,9-10H2/t16-,18-,19+,20-,21+/m1/s1
InChI Key:InChIKey=AHFWIQIYAXSLBA-RQXATKFSSA-N
SMILES:O[C@H]1[C@@H](O[C@H](CO)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC=4C(S3)=CC=CC4)=C(F)C=C2
Synonyme:- (1S)-1,5-Anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-<span class="text-smallcaps">D</span>-glucitol
- (1S)-1,5-Anhydro-1-C-[3-[(1-benzothiophen-2-yl)methyl]-4-fluorophenyl]-D-glucitol
- <span class="text-smallcaps">D</span>-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-, (1S)-
- Asp 1941
- Suglat
- D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-, (1S)-
- (1S)-1,5-Anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-D-glucitol
- Ipragliflozin
- Ipragliflozin, >=98%
- Ipragliflozin, (1S)-1,5-Anhydro-1-C-[3-[(1-benzothiophen-2-yl)Methyl]-4-fluorophenyl]-D-glucitol
- IpragliflozinL-Proline
- IpragliflozinL-Proline int
- Ipragliflozin impuity
- Ipragliflozin Impurity
- ASP-1941/D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylMethyl)-4-fluorophenyl]-, (1S)-
- Ipragliflozin (ASP1941)
- Ipragliflozin-002
- CS-1580
- Ipragliflozin （Suglat）
- Weitere Synonyme anzeigen
Sortieren nach
Reinheit (%)
0
100
|
0
|
50
|
90
|
95
|
100
15 Produkte gefunden.
D-Glucitol,1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-, (1S)-
CAS:Formel:C21H21FO5SReinheit:98%Farbe und Form:SolidMolekulargewicht:404.4518(2S,3R,4R,5S,6R)-2-(3-(Benzo[B]Thiophen-2-Ylmethyl)-4-Fluorophenyl)-6-(Hydroxymethyl)Tetrahydro-2H-Pyran-3,4,5-Triol
CAS:(2S,3R,4R,5S,6R)-2-(3-(Benzo[B]Thiophen-2-Ylmethyl)-4-Fluorophenyl)-6-(Hydroxymethyl)Tetrahydro-2H-Pyran-3,4,5-TriolFormel:C21H21FO5SReinheit:>98%Molekulargewicht:404.45Ipragliflozin-13C6
CAS:Formel:C1513C6H21FO5SFarbe und Form:White To Off-White SolidMolekulargewicht:410.41Ipragliflozin
CAS:Formel:C21H21FO5SReinheit:>95.0%(HPLC)Farbe und Form:White to Light yellow powder to crystalMolekulargewicht:404.45Ipragliflozin
CAS:(2S,3R,4R,5S,6R)-2-(3-(Benzo[b]thiophen-2-ylmethyl)-4-fluorophenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triolFormel:C21H21FO5SReinheit:98%Molekulargewicht:404.45Ipragliflozin
CAS:Ipragliflozin (ASP1941) is under investigation in Type 2 Diabetes and Diabetes Mellitus, Type 2.Formel:C21H21FO5SReinheit:99.38% - 99.70%Farbe und Form:White SolidMolekulargewicht:404.45Ipragliflozin
CAS:Kontrolliertes ProduktApplications Ipragliflozin is a potent and selective inhibitor of sodium-glucose cotransporter-2 (SGLT2) and can serve as a potential agent for the treatment of type 1 and type 2 diabetes.
References Kadokura, T., et al.: Clin. Pharmacokinet., 53, 975 (2014); Kashiwagi, A., et al.: J. Diabetes Investig., 5, 382 (2014); Tahara, A., et al.: J. Pharm. Pharmacol., 66, 975 (2014); Zhang, W., et al.: Clin. Drug Invest., 33, 489 (2013)Formel:C21H21FO5SFarbe und Form:NeatMolekulargewicht:404.45Ipragliflozin
CAS:Inhibitor of sodium-glucose cotransporter SGLT2
Formel:C21H21FO5SReinheit:Min. 95%Farbe und Form:PowderMolekulargewicht:404.45 g/mol
![D-Glucitol,1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-, (1S)-](https://static.cymitquimica.com/products/IN/thumb/DA00ICPF.jpg)
